Two to three weeks after treatment, the previously paralyzed mice began to walk. Credit: Lehrstuhl für Zellphysiologie
To date, paralysis resulting from spinal cord damage has been irreparable. With a new therapeutic approach, scientists from the Department for Cell Physiology at Ruhr-Universität Bochum (RUB) headed by Professor Dietmar Fischer have succeeded for the first time in getting paralyzed mice to walk again. The keys to this are the protein hyper-interleukin-6, which stimulates nerve cells to regenerate, and the way how it is supplied to the animals. The researchers published their report in the Journal Nature Communications from 15 January 2021.
When the communication breaks down
Spinal cord injuries caused by sports or traffic accidents often result in permanent disabilities such as paraplegia. This is caused by damage to nerve fibers, so-called axons, which carry information from the brain to the muscles and back from the skin and muscles. If these fibers are damaged due to injury or illness, this communication is interrupted. Since severed axons in the spinal cord can’t grow back, the patients suffer from paralysis and numbness for life. To date, there are still no treatment options that could restore the lost functions in affected patients.
Designer protein stimulates regeneration
In their search for potential therapeutic approaches, the Bochum team has been working with the protein hyper-interleukin-6. “This is a so-called designer cytokine, which means it doesn’t occur like this in nature and has to be produced using genetic engineering,” explains Dietmar Fischer. His research group already demonstrated in a previous study that hIL-6 can efficiently stimulate the regeneration of nerve cells in the visual system.
In their current study, the Bochum team induced nerve cells of the motor-sensory cortex to produce hyper-Interleukin-6 themselves. For this purpose, they used viruses suitable for gene therapy, which they injected into an easily accessible brain area. There, the viruses deliver the blueprint for the production of the protein to specific nerve cells, so-called motoneurons. Since these cells are also linked via axonal side branches to other nerve cells in other brain areas that are important for movement processes such as walking, the hyper-interleukin-6 was also transported directly to these otherwise difficult to access essential nerve cells and released there in a controlled manner.
Applied in one area, effective in several areas
“Thus, gene therapy treatment of only a few nerve cells stimulated the axonal regeneration of various nerve cells in the brain and several motor tracts in the spinal cord simultaneously,” points out Dietmar Fischer. “Ultimately, this enabled the previously paralyzed animals that received this treatment to start walking after two to three weeks. This came as a great surprise to us at the beginning, as it had never been shown to be possible before after full paraplegia.”
The research team is now investigating to what extent this or similar approaches can be combined with other measures to optimize the administration of hyper-Interleukin-6 further and achieve additional functional improvements. They are also exploring whether hyper-interleukin-6 still has positive effects in mice, even if the injury occurred several weeks previously. “This aspect would be particularly relevant for application in humans,” stresses Fischer. “We are now breaking new scientific ground. These further experiments will show, among other things, whether it will be possible to transfer these new approaches to humans in the future.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Global Top Selling Biologics Report 2021-2030: Monoclonal Antibody, Hormone, Enzyme, Fusion Protein, Interferon, Gene Therapyon August 4, 2021 at 1:08 am
The "Top Selling Biologics Market, 2021-2030: Focus on Product Landscape Assessment, Ongoing Clinical Trials, Promotional Content Analysis, Other Life Cycle Management Strategies, Competition from ...
- Gene Therapy Market 2021: Development, Key Opportunity, Industry Analysis, Regional Overview, Forecast to 2026on August 3, 2021 at 11:09 pm
The global “gene therapy market 2020” is likely to grow at an impressive CAGR over the forecast period, owing to recent technological advancements in gene replacement procedures. According to a report ...
- New McKinsey center to help transform and digitally enable cell- and gene-therapy manufacturingon August 3, 2021 at 8:59 pm
McKinsey’s newest Digital Capability Center will partner with NJII to focus on digital enablement and operational excellence in cell- and gene-therapy manufacturing.
- Watch Now: Gene therapy fights rare diseaseson August 3, 2021 at 9:40 am
The prospect of gene therapy has many scientists and researchers excited. Source by: Stringr Your comment has been submitted. Reported There was a problem reporting this. Log In Please keep it clean, ...
- FDA allows Novartis gene therapy trials to resume after nearly two year pauseon August 3, 2021 at 9:36 am
After reviewing animal study data submitted by the Swiss pharma, the FDA cleared spinal injections of Zolgensma for study in older patients with SMA.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tolloviron July 28, 2021 at 5:58 am
Trials will separately enroll non-hospitalized and hospitalized patientsClinical trials in India targeted to be adaptive design to enable expansion into pivotal development upon achieving data ...
- Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe ...on July 26, 2021 at 1:03 pm
Positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn’s disease patients who had previously failed three or more lines of biologic therapies, ...
- Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patientson July 26, 2021 at 1:01 pm
Positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines ...
- A Blood Filter Fights Deadly Inflammatory Responseon July 20, 2021 at 5:00 pm
A new blood filtration technology may prove to be life-saving for patients whose normally healthy inflammatory response to injury or illness has gone into overdrive, resulting in fatally high levels ...
- Ant venom peptide can activate a pseudo-allergic pathwayon July 12, 2021 at 10:46 am
When an allergic reaction happens, mast cells that line the body surfaces alert the immune system by releasing cytokines ... this novel information, we can design new analogs that are agonists ...